Last reviewed · How we verify
SH P00331N
SH P00331N is a small molecule drug that targets the SGLT2 receptor.
SH P00331N is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | SH P00331N |
|---|---|
| Sponsor | Bayer |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
SH P00331N works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, which reduces glucose reabsorption and increases glucose excretion in the urine. This leads to a decrease in blood glucose levels. By targeting SGLT2, SH P00331N helps to lower blood glucose levels in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
- Increased risk of genital yeast infections
- Increased risk of urinary tract infections
Key clinical trials
- FC Patch Comparator Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SH P00331N CI brief — competitive landscape report
- SH P00331N updates RSS · CI watch RSS
- Bayer portfolio CI